FDA
-
-
-
-
-
-
-
Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion
-
-
-
-
-
-
-
FDA approves Bristol Myers Squibb's Sotyktu for psoriatic arthritis
-
-
-
-
-
-
-
Bristol-Myers Squibb receives orphan drug designation for lymphoma treatment
-
-
-
-
-
-
-
Bristol Myers Squibb's Camzyos meets primary endpoint in adolescent trial
-
-
-
-
-
-
-
FDA approves Bristol Myers Squibb Breyanzi for marginal zone lymphoma
-
-
-
-
-
-
-
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
-
-
-
-
-
-
-
Bristol Myers Squibb shows long-term Sotyktu efficacy data
-
323,150 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

